Julie Rubinstein


Julie Rubinstein is the President of Adaptive Biotechnologies. Ms. Rubinstein joined Adaptive in 2011 as the head of Corporate and Business Development. In 2016, she became the Chief Business Officer and led the company’s Life Sciences Research Business through two years of double-digit growth. Then, in February 2018, she began serving as President, overseeing the expansion of all of the business lines including Life Sciences Research, Clinical Diagnostics, and Drug Discovery, with continued oversight of Corporate and Business Development functions. Prior to joining Adaptive, Ms. Rubinstein held various worldwide commercial development roles at Pfizer Oncology, primarily focusing on cancer immunotherapy. She also held multiple positions at Johnson & Johnson’s Ethicon Endo-Surgery division, where she helped commercialize a breast cancer diagnostic device in major European markets. She began her career in Morgan Stanley’s Global Health Care Group as a financial analyst. Ms. Rubinstein holds a dual degree, Summa Cum Laude and Phi Beta Kappa, from the University of Pennsylvania’s Undergraduate Wharton School and Annenberg School of Communications, with a minor in French. She also holds an MBA from Harvard Business School. She currently serves on the Board of Trustees for The Valerie Fund, a pediatric oncology organization in New Jersey and New York.